Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, Armstrong P, McAuley J, Madden S, Fay J, Sheehan KM, Kay EW, Holohan C, Elamin Y, Rafee S, Morris PG, Breathnach O, Grogan L, Hennessy BT, Toomey S.
Mezynski MJ, et al. Among authors: farrelly am.
J Transl Med. 2021 May 1;19(1):184. doi: 10.1186/s12967-021-02842-1.
J Transl Med. 2021.
PMID: 33933113
Free PMC article.